Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT01691898
Title A Study of Pinatuzumab Vedotin (DCDT2980S) Combined With Rituximab or Polatuzumab Vedotin (DCDS4501A) Combined With Rituximab or Obinutuzumab in Participants With Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma (ROMULUS)
Recruitment Completed
Gender both
Phase Phase Ib/II
Variant Requirements No
Sponsors Genentech, Inc.
Indications

diffuse large B-cell lymphoma

follicular lymphoma

Therapies

Obinutuzumab + Pinatuzumab Vedotin + Rituximab

Pinatuzumab Vedotin + Polatuzumab vedotin-piiq + Rituximab

Obinutuzumab + Polatuzumab vedotin-piiq

Age Groups: senior | adult
Covered Countries USA | ITA | FRA | DEU | CAN


No variant requirements are available.